Pangaea at IAC in Rome - Plumley Co-Moderates Panel on Treatment 2.0: Meeting the Challenges of the Next Phase of HIV Treatment and Prevention

July 14, 2011

The world's largest open scientific conference on HIV/AIDS – the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) will be held in Rome Italy in July 2011.  Pangaea Global AIDS Foundation's presence at the conference is summarized below.

Monday, July 18th
18:30 – 20:30

Session Title: Treatment 2.0: Meeting the Challenges of the Next Phase of HIV Treatment and Prevention
Session Room: Mini Room 4

Introduction:

The past year has brought tremendous advances in the understanding of how to provide more effective HIV treatment and prevention throughout the world. Last week, the United Nations General Assembly committed to bold new treatment and prevention targets.  WHO's treatment guidelines now recommend earlier use of ARV treatment.  And the impact of treatment on HIV transmission provides important new opportunities to better utilize an array of prevention interventions more effectively.  The Satellite Session will be co-sponsored by Pangaea Global AIDS Foundation and the International AIDS Society and will provide further information to conferees about what is now needed in order to realize these goals.

The session will be moderated by Bertrand Audoin, IAS Executive Director, and Ben Plumley, Pangaea's CEO.

Program and Speakers:

  • Overview of Progress on Treatment 2.0, Overview of Framework for Action:  Bernhard Schwartlander, MD (UNAIDS) & Gottfried Hirnschall, MD  (WHO)

  • Improving  Treatment Diagnostic and Monitoring – A Funder's Perspective:  Ambassador Eric Goosby, MD, US Department of State

  • Adapting Delivery Systems - Decentralization and Integration:  Frank Chimbwandira, Malawi National HIV Programme Manager

  • Community Mobilization & Expanding Community-based Delivery:  Bactrin Killingo, MD, Africa Program Manager, International Treatment Preparedness Coalition (ITPC)

  • The Role of the Private Sector: Dominique Limet, ViiV Healthcare

  • Priorities for Drug Optimization:  Dave Ripin, Clinton Health Access Initiation (CHAI)

  • Priority Medicines and the Medicines Patent Pool: Ellen t'Hoen, Executive Director, Medicines Patent Pool

The panel presentation will be followed by a moderated discussion and questions from the audience. This is a public session open all conferees.

Tuesday, July 19th
16:30 – 18:00

Session Title: Retention in the Care Cascade
Session Room: Session Room 3

Introduction:

Dr. Barrot Lambdin, Pangaea's Director of Implementation Science, will be presenting the results of a retrospective cohort study he conducted regarding the delivery of HIV treatment in clinics within Manica and Sofala provinces of Mozambique. In 2004, the Mozambican Ministry of Health (MOH) began a national scale-up of anti-retroviral therapy (ART) services using a vertical model of HIV-specific clinics co-located within large, urban hospitals. The MOH expanded access in 2006 by initiating integrated ART services into primary health care clinics across the country. This particular study examines the relationship of clinic characteristics with patient attrition from HIV treatment programs which will inform the implementation of ART services in the region.

The full abstract will be posted here at a later date, to respect the International AIDS Society Embargo policy.

About the conference:

The world's largest open scientific conference on HIV/AIDS – the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) will be held in Rome Italy in July 2011. The event will be organized by the IAS, in partnership with Istituto Superiore di Sanità (Italian National Institute of Health), which is the leading technical and scientific body of the Italian National Health Service.  Held every two years, the conference attracts about 5,000 delegates from all over the world. It is a unique opportunity for the world's leading scientists, clinicians, public health experts and community leaders to examine the latest developments in HIV-related research, and to explore how scientific advances can – in very practical ways – inform the global response to HIV/AIDS.

 

 

 


 

Secondary menu